Catalyst
Slingshot members are tracking this event:
Novartis (NVS) agrees to license to PureTech Health two mTORC1 inhibitors in studying age-related focuses. New ew subsidiary called resTORbio will head developments of these candidates.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 24, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Restorbio, License, Mtorc1 Inhibitors
